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A
 
BSTRACT
 
Sulfasalazine (salazosulfapyridine) has been used
increasingly and successfully for the treatment of rheu-
matoid arthritis. Azulfidine
 
®
 
EN (salazosulfapyridine;
Pharmacia KK Diagnostics, Tokyo, Japan), which
dissolves in the intestine, is an improvement over
sulfasalazine in terms of diminishing adverse gastro-
intestinal effects. We report herein on a case treated
with salazosulfapyridine for rheumatoid arthritis who
developed mild dyspnea on exertion, high fever and
diffuse pulmonary infiltrates, reversible on discontinu-
ation of the drug. A histologic diagnosis of acute
organizing interstitial pneumonia was made by trans-
bronchial lung biopsy. Because the results of a
lymphocyte stimulation test against Azulfidine
 
®
 
EN
were negative, we allowed the patient to resume
Azulfidine
 
®
 
EN for pain in his elbows under informed
consent. However, the patient developed symptoms of
fever, dry cough and stomatitis and mild renal dys-
function after two doses. Salazosulfapyridine was
permanently discontinued and the patient’s symptoms
subsided. Laboratory findings returned to normal
within 2 weeks. Azulfidine
 
®
 
EN should be added to the
list of pharmacologic agents causing infiltrative pul-
monary disease and renal dysfunction.
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I
 
NTRODUCTION
 
Sulfasalazine (salazosulfapyridine) has been used
increasingly and successfully for the treatment of rheu-
matoid arthritis.
 
1
 
 Adverse gastrointestinal reactions are
most common and may affect one-third of patients.
 
2
 
Azulfidine
 
®
 
EN (Pharmacia KK Diagnostics, Tokyo,
Japan), which is an equivalent drug product absorbed
preferably in the intestine, is an improvement over
sulfasalazine in terms of diminishing adverse gastrointes-
tinal effects. Although several cases of pulmonary infil-
trates due to sulfasalazine can be found in the
literature,
 
3,4
 
 no similar reactions to Azulfidine
 
®
 
EN have
been found. We report herein a case of pulmonary
infiltrate and interstitial nephritis induced by Azulfi-
dine
 
®
 
EN during the course of treatment of rheumatoid
arthritis.
 
C
 
ASE
 
 
 
REPORT
 
Clinical summary
 
A 70-year-old man was admitted to the Division of
Internal Medicine, Saiseikai Kanazawa Hospital, on
25 April 2000 because of high fever and mild dyspnea
on exertion. Chest X-ray on admission revealed diffuse
reticulolinear shadows in the bilateral lung fields (Fig. 1).
An additional history revealed that the patient had a
diagnosis of rheumatoid arthritis since 1992 and had
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undergone bilateral total knee arthroplasty, right total
elbow arthroplasty, right wrist arthroplasty (1996), left
total elbow arthroplasty (1997), posterior cervical fusion
(1998), had been taking 5 mg prednisolone daily and
12 mg methotrexate (MTX) weekly for the treatment of
rheumatoid arthritis for 7 months and that in the past 15
days Azulfidine
 
®
 
EN 1000 mg daily had been added.
The patient had never smoked.
Physical examination revealed the following: body
temperature 36.8
 
°
 
C; blood pressure 110/60 mmHg;
heart rate 90 b.p.m. The conjunctivae were not anemic
or icteric. Cardiac examination was entirely within normal
limits. Auscultation of the lungs revealed late inspiratory
fine crackles bilaterally without wheezes or rhonchi. There
was no lymphadenopathy. The abdomen was benign and
without organomegaly. Severe deformity of the bilateral
elbow joints was seen (stage IV; Steinbrocker 
 
et al.
 
5
 
).
The white blood cell count was 10 500 /
 
µ
 
L with a
differential of 87.5% segmented neutrophils, 4.7% lym-
phocytes, 5.9% monocytes and 1.7% eosinophils. The
erythrocyte sedimentation rate was 78 mm/h. The C-
reactive protein (CRP) was 26.4 mg/dL, creatinine was
1.1 mg/dL, blood urea nitrogen was 17 mg/dL, rheuma-
toid factor was negative, the total IgE level was 69 U/mL
and KL-6 was 556 U/mL. Arterial blood gas levels while
breathing room air were: 
 
P
 
a
 
O
 
2
 
 71.1 mmHg, 
 
P
 
a
 
CO
 
2
 
44.3 mmHg, HCO
 
3
 
 30.5 mmol/L and pH 7.45. The
following laboratory findings were normal or negative:
urinalysis, stools for ova and parasites, serum electro-
lytes, total protein and albumin, and mycobacterial and
fungal cultures of sputum. The electrocardiogram showed
normal sinus rhythm.
A chest computed tomography (CT) scan on admis-
sion (Fig. 2) showed diffuse ground glass-like opacities
with fine reticulonodular shadows in both lung fields.
The pulmonary function test, performed according
to the standards of the American Thoracic Society,
 
6
 
revealed forced vital capacity (FVC) 2.19 L (72.3% of
predicted), forced expiratory volume in 1 s (FEV
 
1
 
) 1.62 L
(82.7% of predicted), FEV
 
1
 
/FVC ratio 74.0%, total lung
capacity 3.87 L (85.2% of predicted), residual volume
 
Fig. 1
 
Chest X-ray on admission revealing diffuse reticulo-
linear shadows in the bilateral lung fields.
 
Fig. 2
 
Chest computed tomography scan on admission show-
ing diffuse ground glass-like opacities with fine reticulonodular
shadows in both lung fields.
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1.62 L (99.4% of predicted), diffusing capacity of the
lung for carbon monoxide (DLco) 15.2 mL/min per mmHg
(70.6% of predicted) and the gas transfer coefficient
(DLco/VA) 5.11 mL/min per mmHg per L (116.1% of
predicted). Because drug-induced pneumonitis was also
suspected from the patient’s clinical course, Azulfidine
 
®
 
EN
was discontinued and cefazolin sodium (2 g/day) was
administered. Within 7 days, the patient’s fever and
dyspnea were resolved and CRP decreased to1.6 mg/dL.
Because the results of a lymphocyte stimulation test
against Azulfidine
 
®
 
EN were negative (245 c.p.m./144%),
we allowed the patient to resume Azulfidine
 
®
 
EN for pain
in his elbows under informed consent. However, he
developed symptoms of fever (38.4
 
°
 
C), dry cough and
stomatitis and mild renal dysfunction after two doses.
Renal biopsy revealed interstitial nephritis. No blood
eosinophilia occurred. Azulfidine
 
®
 
EN was permanently
discontinued. The patient’s symptoms subsided and labora-
tory findings returned to normal within 2 weeks (Fig. 3).
 
Pathologic findings
 
Bronchoalveolar lavage (BAL) was performed using a
total volume of 100 mL sterile saline solution (49%
recovery). Cytologic examination showed an increased
absolute total cell count of 2.6 
 
×
 
 10
 
6
 
 cells/mL and 80%
alveolar macrophages, 2% neutrophils and 18% lym-
phocytes. Bronchoalveolar lavage lymphocyte subsets
revealed the presence of CD4
 
+
 
 cells (63.3%) and CD8
 
+
 
cells (30.4%). The CD4/CD8 ratio was 2.08.
 
Fig. 3
 
Clinical course. After resuming treatment with Azulfidine
 
®
 
EN (Pharmacia KK Diagnostics, Tokyo, Japan) under informed
consent, the patient developed symptoms of fever, dry cough and stomatitis and mild renal dysfunction after two doses. Azulfidine
 
®
 
EN
was permanently discontinued and the patient’s symptoms subsided and laboratory findings returned to normal within 2 weeks.
CRP, C-reactive protein; WBC, white blood cell count; Cr, creatinine; BUN, blood urea nitrogen.
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Transbronchial lung biopsy obtained from the right
S
 
8
 
a showed edematous alveolar septa with mild lym-
phocyte infiltration and intraluminal organization in a
fashion of Masson’s bodies (Fig. 4), namely acute organ-
izing interstitial pneumonia.
 
D
 
ISCUSSION
 
A number of drugs have been reported to cause pulmo-
nary infiltrates
 
1–12
 
 and non-steroidal anti-inflammatory
drugs have been implicated as etiologic factors for acute
interstitial pneumonia.
 
8
 
Salazosulfapyridine has been widely used for the treat-
ment of ulcerative colitis, Crohn’s disease and, more
recently, for rheumatoid arthritis.
 
1
 
 Only 15 cases of pul-
monary complications induced by this drug have been
reported.
 
3,4
 
 Most of cases suffered from inflammatory
bowel diseases as described above. Two distinct patterns
of pulmonary lesion have been reported: (i) eosinophilic
pneumonia;
 
11,12
 
 and (ii) fibrosing alveolitis.
 
13,14
 
 The prog-
nosis of eosinophilic pneumonia is generally good after
discontinuation of the causative drug, whereas that of
fibrosing alveolitis is less preferable and sometimes fatal
in spite of steroid therapy.
In the present case, eosinophils were not seen in the
BAL fluid, peripheral blood or the transbronchial lung
biopsy specimen. However, the findings of mild alveolitis
with tiny luminal organization can be categorized as
allergic pneumonitis. The pulmonary lesion in the present
case was strictly neither eosinophilic pneumonia nor
fibrosing alveolitis, but was not far from these entities. If
the discontinuation of the drug was delayed, fibrosing
alveolitis could follow.
 
13,14
 
Although adverse effect profiles of 5-aminosalicylates,
such as sulfasalazine and mesalazine, have been cate-
gorized for interstitial nephritis, pancreatitis, serious skin
reactions, hepatitis and blood dyscrasias, interstitial
nephritis was only described for mesalazine.
 
15,16
 
 In the
present case, the patient developed mild renal dysfunc-
tion after two doses of salazosulfapyridine and renal
biopsy revealed interstitial nephritis.
It is important to be aware of the possibility of acute
organizing interstitial pneumonia occurring in patients
treated with not only sulfasalazine, but also Azulfidine
 
®
 
EN,
and of interstitial nephritis with not only mesalazine, but
also sulfasalazine.
It is well known that 5-aminosalicylates have a wide
range of adverse effects. Because the sustained-
release formula Azulfidine
 
®
 
EN may also have the same
adverse reactions, it is necessary to pay attention to its
adverse effects, especially pulmonary and renal com-
plications, when seeing patients receiving this formula.
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